MedPageToday
MedPage Today) — SAN FRANCISCO — Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin analog (SSA) lanreotide (Somatuline Depot) to everolimus (Afinitor…
Read More
Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy
MedPage Today) — SAN FRANCISCO — Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin analog (SSA) lanreotide (Somatuline Depot) to everolimus (Afinitor…